Biohit Oyj - Notice to general meeting

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS OF BIOHIT OYJ

The shareholders of Biohit Oyj are invited to the Annual General Meeting of
Shareholders to be held on Wednesday, 13 April 2011 at 3:00 p.m. at Palace
Gourmet at Eteläranta 10, Helsinki. 

The reception of registered attendants and distribution of ballot papers at the
venue of the meeting begins at 2:00 p.m. 

A. MATTERS TO BE DEALT WITH BY THE GENERAL MEETING

The following matters will be dealt with by the General Meeting:

1. Opening the meeting

2. Calling the meeting to order

3. Election of persons to scrutinize the minutes and to supervise the counting
of votes 

4. Recording the attendance at the meeting and adoption of the list of votes

5. Recording the legality and quorum of the meeting

6. Presentation of the Financial Statements, the Report of the Board of
Directors and the Auditor's Report for 2010 and Review by the CEO 

7. Adoption of the Financial Statements

8. Resolution on the use of the result shown on the Balance Sheet

The Board of Directors proposes that the loss for the financial period is
transferred to retained losses and that no dividend be paid. 

9. Resolution on the discharge of the members of the Board of Directors and the
CEO from liability 

10. Resolution on the number and remuneration of the members of the Board of
Directors 

11. Election of members of the Board of Directors

12. Resolution on the remuneration of the Auditor

The Board of Directors proposes to the General Meeting that the Auditor be
remunerated in accordance with his/her invoice. 

13. Election of Auditor

Shareholders representing more than 50% of all voting rights produced by the
company's shares have announced that they will propose to the General Meeting
that Authorised Public Accountants Ernst & Young Oy be elected as Auditors
until the end of the next Ordinary General Meeting. 

14. Authorisation of the Board of Directors to decide on the issue of shares
and to issue special rights entitling the receipt of shares 

The Board of Directors proposes that the General Meeting authorises the Board
to decide on the issue of shares and to issue special rights referred to in
Chapter 10, section 1 of the Limited Liability Companies Act entitling the
receipt of shares with the following terms and conditions: 

The maximum number of new Series B shares to be issued pursuant to the special
rights is 2,000,000, which corresponds to approximately 20% of the company's
Series B shares. 

The authorisation includes the Board of Directors' entitlement to decide on all
terms and conditions regarding the issue of special rights. The issue of shares
and the issue of special rights entitling to the receipt of shares can occur
deviant from the subscription right of the shareholders (special issue). 

The authorisation remains valid for three years from the resolution of the GM.

15. Closing the meeting

B. DOCUMENTS OF THE GENERAL MEETING

The above proposals of the Board of Directors, included in the agenda of the
General Meeting, are available on Biohit Oyj's website at
www.biohit.com/investors. 

The Financial Statements, Consolidated Financial Statements, the Report of the
Board of Directors of Biohit Oyj and the Corporate Governance Statement, as
well as the Auditor's Report are available on the above website and at the
company's headquarters at Laippatie 1, 00880 Helsinki. 

The Board's proposals and financial statements will also be available at the
General Meeting, and copies of them and of this notice will be sent to
shareholders by request. 

C. INSTRUCTIONS FOR PARTICIPANTS IN THE GENERAL MEETING

1. The right to participate and registration

The shareholders who on the General Meeting record date of 1 April 2011 are
registered in the shareholder register maintained by Euroclear Finland Oy have
the right to participate in the General Meeting of Shareholders. Any
shareholder whose shares are registered on his/her personal Finnish book-entry
account is registered in the company's shareholder register. 

Shareholders wishing to participate in the General Meeting must register their
participation in the General Meeting. Registration begins on 15 March 2011 at
12 p.m. and terminates on 8 April 2011 at 4:00 p.m. 

Registration occurs:

a)    At www.biohit.com/investors
b)    By e-mail at yhtiokokous@biohit.com;
c)    By telephone: +358 9 773 861;
d)    By a letter sent to: Biohit Oyj, Yhtiökokous, Laippatie 1, 00880 Helsinki

When registering for the meeting, the following details shall be provided: the
shareholder's name, personal identity number, address and telephone number as
well as the name of any proxy representative or assistant to be used, and the
personal identity number of the assistant. The personal data given by
shareholders to Biohit Oyj will only be used in connection with the General
Meeting and for processing the necessary registrations. 

Pursuant to Chapter 5, section 25 of the Finnish Limited Companies Act, a
shareholder who is present at the General Meeting has the right to request
information with respect to the matters to be considered at the meeting. 

2. Proxy representatives and powers of attorney

A shareholder may participate in the General Meeting and exercise his/her
rights at the meeting through proxy representation. A shareholder may have
several proxy representatives representing the shareholder with shares at
different securities accounts. In such a case, the shares with which each proxy
representative represents the shareholder shall be specified at the time of
registration. 

A proxy representative shall produce a dated proxy document or otherwise
demonstrate, in a reliable manner, his/her right to represent the shareholder
at the meeting. Any proxy documents should be delivered as originals no later
than 4 p.m. on 8 April 2011 to Biohit Oyj, Yhtiökokous, Laippatie 1, 00880
Helsinki. 

3. Holders of nominee registered shares

If a holder of nominee registered shares is entitled to be registered in the
company's share register on the record date of 1 April 2011, the shareholder
may, in accordance with the instructions provided by his/her asset manager, ask
to be temporarily entered into the company's shareholder register for
participation in the General Meeting on 8 April 2011 at 10 a.m. at the latest.
The holder of nominee registered shares is deemed to have registered for the
General Meeting if he/she was registered for a temporary entry in the
shareholder register in the manner described above. 

The holder of nominee registered shares is advised to request his/her asset
manager to provide the necessary instructions for temporary registration in the
company's shareholder register, the issuing of proxy documents and registration
for the General Meeting. 

4. Other information

On 15 March 2011, the date of the notice of GM, the share capital of Biohit Oyj
consists of a total of 12,937,627 shares. The shares are divided into Series A
and Series B shares. The total number of Series A shares is 2,975,500,
producing a total of 59,510,000 votes, while the total number of Series B
shares is 9,962,127, producing a total of 9,962,127 votes. 

Helsinki 15 March 2011


Biohit Oyj
Board of Directors



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com

About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services for research
institutions, healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the early
diagnosis and prevention of gastrointestinal diseases, such as the blood-sample
based GastroPanel examinations for the diagnosis of stomach illnesses and
associated risks, quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy, and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in
an anacidic stomach. 

The Biohit Group employs around 420 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are also sold through about 200 distributors in
70 countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV. 

Read more at www.biohit.com